ZYBERNO
Stock Report
Updated Jun 8, 2026

Valion Bio, Inc. (TIVC)

Healthcare • NASDAQ

$0.76

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
9.0/100
POOR BUSINESS
Valion Bio, Inc. (TIVC) scores 9/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-146.2%)
Debt-to-Equity (Solvency Risk):POOR (1.83x)
Operating Margin (Operational Efficiency):CRITICAL (-2,495.0%)
Return on Capital (Capital Efficiency):CRITICAL (-79.4%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Valion Bio, Inc. (TIVC) stock report — Zyberno Score 9/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.76
Market Cap:$2.19M

Valuation Multiples (3)

P/B Ratio:0.20x
P/S Ratio:4.55x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$6.27M
B. Profitability Assessment

Return Metrics (5)

ROA:-67.4%
Reinvestment Rate:-0.3%
Fundamental Growth Rate (g):0.2%

Margin Analysis (3)

Operating Margin Ttm:-2,495.0%
Net Margin Ttm:-2,817.0%
Ebitda Margin:-2,492.9%

TTM Performance (3)

Gross Margin Ttm:-17.2%
Operating Margin Ttm:-2,495.0%
Net Margin Ttm:-2,817.0%

Yield Metrics (2)

Earnings Yield:-$3.03K
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:21.4%
Latest Earnings Filed:2025-08-14

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-32.9%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:3.31x
Quick Ratio:3.02x
Cash Ratio:2.76x

Leverage Analysis (3)

Debt To Equity Ttm:1.83x
Debt-to-Equity Ratio:1.83x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-6.82x
Times Interest Earned:-6.82

Capital Structure (4)

Working Capital:6,037,000.00
Cash And Cash Equivalents:7,215,000.00
Long Term Debt:$9.64M
Net Debt:$4.08M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $482.00K
Linear Growth: -32.9%
📊 Click to view full TIVC Revenue analysis & methodology →
Cost Of Revenue Ttm:$762.00K

Profitability Breakdown (2)

Gross profit TTM: -$83.00K
Linear Growth: -6.9%
📊 Click to view full TIVC Gross Profit analysis & methodology →
-$12.03M

Bottom Line Performance (3)

-$13.58M
Income Before Tax:$8.90M
Ebitda Ttm:-12,016,000.00

Operating Expenses (5)

Operating Expenses:11,976,000.00
R And D Expense:4,650,000.00
Sga Expense:7,505,000.00
Income Tax Expense:$0.00
Interest Expense:656,000.00

Expense Ratios (3)

R And D To Revenue Percentage:3,184.9%
Sga To Revenue Percentage:5,140.4%
Ebitda Margin:-2,492.9%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$38.22M
Current Assets:$8.65M
Ppe Net:12,644,000.00
Goodwill:3,457,000.00
Intangible Assets:$2.24M

Liability Structure (4)

Total Liabilities:27,153,000.00
Current Liabilities:2,615,000.00
Long Term Debt:$9.64M
Short Term Debt:$1.65M

Equity & Capital (3)

Equity:$11.06M
Retained Earnings:-$59.03M
Common Stock:200,000,000.00

Working Capital Items (3)

Accounts Receivable:19,000.00
Inventory:750,000.00
Accounts Payable:629,000.00

Special Items (2)

Contract Liabilities:3,000.00
Stock Based Compensation:208,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$11.12M-$7.04M

Investment Activities (1)

Investing Cash Flow:-$7.00K

Financing Activities (3)

Financing Cash Flow:-$44.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:8,507,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:10,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-7.55
-$23.06
Earnings Per Share Ttm:-$4.71

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.17
Operating Cash Flow Per Share:-$1.99

Book Value & Capital (2)

Book Value Per Share:$3.84
Cash Per Share:2.50

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.02x
Working Capital Turnover Ttm:0.08x

Receivables Management (2)

Receivables Turnover Ttm:25.37x
Days Sales Outstanding Ttm:14.39

Inventory Management (2)

Inventory Turnover Ttm:1.02x
Days Inventory Outstanding Ttm:359.25

Payables & Cash Cycle (2)

Days Payable Outstanding:301.29
Cash Conversion Cycle:72.35
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:-0.3%
Fundamental Growth Rate (g):0.2%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-32.9%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):-6.9%
Book Value Growth Rate (Linear):-1.3%
C. Company Profile & Context

Corporate Information (6)

Symbol:TIVC
Company Name:Valion Bio, Inc.
Sector:Healthcare
Industry:Medical Technology
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:2.88M
Shares Outstanding Basic:2.88M
Shares Outstanding Diluted:881.29K

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-06-08 14:28:35 UTC
Data Timestamp:2026-06-08T14:28:35.730235
Scroll to Top